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Introduction
Bullous pemphigoid (BP) is an acquired autoimmune
skin disease characterized by autoantibodies against two
hemidesmosomal antigens, BP230 (BPAG1) and BP180
(BPAG2), and subepidermal blisters (1). These anti-
hemidesmosomal autoantibodies can be detected, along
with complement proteins, bound to the dermal-epider-
mal junction (DEJ) of perilesional skin. In the skin lesions
of these patients, basal keratinocytes detach from the
underlying dermis at the level of the lamina lucida, lead-
ing to subepidermal blistering (1, 2). Eosinophils (3, 4),
neutrophils (5), lymphocytes (6), monocyte/macrophages
(7, 8), and mast cells (MCs; 7, 9) are present in the upper
dermis of lesional areas in patients with BP. Interesting-
ly, MC degranulation is a feature of BP (7, 9). Chemoat-
tractants from MCs, including eosinophilic/neutrophilic
chemotactic factors and histamine, are present at high
concentrations in BP blister fluids (10, 11). Similar skin
lesions are observed in the pregnancy-associated nonvi-
ral disorder herpes gestationis (12). These observations
imply that MCs may play a role in blister formation.
We have used an experimental model of BP that
involves the passive transfer of anti-mBP180 antibod-
ies into neonatal BALB/c mice to reproduce the key
immunopathological features of this human autoim-
mune disease: IgG and complement deposition at the
DEJ, inflammatory infiltration of the upper dermis,
and subepidermal blistering (13). The pathogenicity of
anti-mBP180 antibodies depends on complement acti-
vation (14) and polymorphonuclear leukocyte (PMN)
recruitment (15). In the present study, we have investi-
gated the role of MCs in experimental BP using mice
genetically deficient in MCs.
Methods
Laboratory animals. Breeding pairs of MC-deficient
WCB6F1-MgfSl/MgfSl-d (referred to as MgfSl/MgfSl-d), MC-
deficient WBB6F1-Kitw/Kitw-v (referred to as Kitw/Kitw-v),
and the congenic MC-sufficient (MC+/+) littermates (16)
and C5-deficient B10-D2-OSN (C5–) and their matched
normal control B10-D2-NSN (C5+) mice were pur-
chased from The Jackson Laboratory (Bar Harbor,
Maine, USA) and maintained at the Medical College of
Wisconsin Animal Resource Center and the University
of North Carolina at Chapel Hill Animal facility. The
MC deficiency in MgfSl/MgfSl-d and Kitw/Kitw-v mice are
caused by distinct mutations in MC growth factor and
c-Kit, respectively (16). Neonatal mice (24–36 hours old,
1.4–1.6 g) were used for passive transfer experiments.
Preparation of pathogenic rabbit anti-mouse IgG. The
preparation of recombinant mBP180 and the immu-
nization of rabbits were performed as described previ-
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MCs or MC-sufficient mice pretreated with an inhibitor of MC degranulation failed to develop BP. Fur-
ther, MC-deficient mice reconstituted in skin with MCs became susceptible to experimental BP. Despite
the activation of complement to yield C3a and C5a, in the absence of MCs, accumulation of neutrophils
at the injection site was blunted. The lack of response due to MC deficiency was overcome by intrader-
mal administration of a neutrophil chemoattractant, IL-8, or by reconstitution of the injection sites
with neutrophils. These findings provide the first direct evidence to our knowledge that MCs play an
essential role in neutrophil recruitment during subepidermal blister formation in experimental BP.
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ously (13). The titers of rabbit anti-mBP180 antibodies
in the rabbit sera and in the purified IgG fractions were
assayed by indirect immunofluorescence (IF) using
mouse skin cryosections as substrate (13). The patho-
genicity of these IgG preparations were tested by pas-
sive transfer experiments, as described below.
Induction of experimental BP and animal evaluation. A 50-
µl dose of sterile IgG in PBS was administered to neona-
tal mice by intradermal injection (2.5 mg IgG per gram
of body weight) as described previously (13, 15). The
skin of neonatal mice from the test and control groups
was examined 12 hours after the IgG injection. The
extent of cutaneous disease was scored as follows: (–), no
detectable skin disease; 1+, mild erythematous reaction
with no evidence of the “epidermal detachment” sign
(this sign was elicited by gentle friction of the mouse
skin, which, when positive, produced fine, persistent
wrinkling of the epidermis); 2+, intense erythema and
epidermal detachment sign involving 10–50% of the
epidermis in localized areas; and 3+, intense erythema
with frank epidermal detachment sign involving more
than 50% of the epidermis. The animals were then
killed, and skin and serum specimens were obtained.
Skin sections were taken for light microscopy (hema-
toxylin and eosin [H&E] staining) and for direct IF
analysis to detect rabbit IgG and mouse C3 deposition
at the basement membrane zone (BMZ). Sera of inject-
ed animals were used for indirect IF assay to determine
the circulating titers of anti-mBP180 IgG. Direct and
indirect IF analyses were performed as described previ-
ously (13). Monospecific FITC-conjugated goat anti-
rabbit IgG was purchased from Kirkegaard & Perry Lab-
oratories Inc. (Gaithersburg, Maryland, USA);
monospecific goat anti-mouse C3 was purchased from
Cappel Laboratories (Durham, North Carolina, USA).
Quantification of PMN accumulation at the skin site.
Myeloperoxidase (MPO) activity in skin sites of the
injected animals was assayed as a measure of PMN infil-
tration as described elsewhere (17, 18). A standard ref-
erence curve was established using purified MPO
(Athens Research and Technology Inc., Athens, Georgia,
USA). The skin samples were extracted by homogeniza-
tion in an extraction buffer containing 0.1 M Tris-Cl
(pH 7.6), 0.15 M NaCl, and 0.5% hexadecyl trimethy-
lammonium bromide. MPO activity in the supernatant
fraction was measured by the change in optical density
at 460 nm resulting from decomposition of H2O2 in the
presence of o-dianisidine. MPO content was expressed
as units of MPO activity per milligram of protein. Pro-
tein concentrations were determined by the Bio-RAD
dye-binding assay (Bio-Rad Laboratories Inc., Hercules,
California, USA) using BSA as a standard.
Quantification of MCs and MC degranulation. MCs and MC
degranulation in skin samples were quantified according
to Wershil et al. (19) with modification. Briefly, lesional
and nonlesional skin sections of IgG-injected mice were
fixed in 10% formalin. Paraffin sections (5 µm thick) were
prepared and stained with toluidine blue and H&E. The
total number of MCs was counted and classified as
degranulated (>10% of the granules exhibiting fusion or
discharge) or normal in five fields under a light micro-
scope as described previously. The results were expressed
as percentage of MC degranulating.
Electron microscopic analysis of MC morphology. The skin
samples were dissected from the injected sites of the
test and control animals and immersed in a fixative of
2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2).
The tissue blocks were post-fixed with OsO4 and then
dehydrated with a series of graded ethanol. Thin sec-
tions were contrasted with uranyl acetate and lead cit-
rate and examined with a Hitachi-600 transmission
electron microscope (Hitachi Instruments Inc., San
Jose, California, USA) at 75 KV.
In vivo inhibition of MC degranulation. Neonatal wild-
type mice were injected intradermally with pathogenic
IgG (2.5 mg per gram of body weight) in the absence or
presence of cromolyn sodium (Sigma Chemical Co., St.
Louis, Missouri, USA) (10 µg per gram of body weight),
an MC degranulation inhibitor (20, 21). The animals
were examined for clinical blisters 12 hours after IgG
injection, and the skin sections were analyzed by IF,
H&E, and toluidine blue staining. Skin PMN infiltra-
tion was quantified by MPO assay.
PMN isolation. Mouse PMNs were isolated from
heparinized blood by dextran sedimentation followed
by separation on a density gradient as described previ-
ously (22). Red blood cells were removed from the cell
preparation by hypotonic lysis in 0.2% NaCl. PMNs
were washed and resuspended in cold PBS/10 mM glu-
cose, counted in a hemocytometer, and adjusted to a
concentration of 1 × 107 cells/ml. PMN purity of the
final cell preparation was consistently more than 96%
as determined by cell-cytospin and LeukoStat staining
(Fisher Diagnostics, Orangeburg, New York, USA). The
viability of the neutrophils was >96% as determined by
trypan blue exclusion.
Intradermal injection of PMNs. PMNs were purified from
MC-deficient and MC+/+ mice. MC-deficient mice were
injected intradermally with pathogenic anti-mBP180
IgG (2.5 mg per gram of body weight per 50 µl PBS).
Two hours later, these mice were injected with 5 × 105
PMNs intradermally (in 50 µl of PBS/10 mM glucose)
at the same site (23). The animals were analyzed 12
hours after the IgG injections, as described above.
IL-8 pretreatment of MC-deficient mice. Recombinant
human IL-8 (hIL-8; R&D Systems Inc., Minneapolis,
Minnesota, USA) was stored at 1 mg/ml in sterile
PBS. A single intradermal injection of IL-8 (50 ng in
50 µl PBS) or an equivalent amount of BSA was given
to neonatal MC-deficient mice, followed by intrader-
mal injection of rabbit anti-mBP180 IgG (2.5 mg per
gram of body weight in 50 µl) 1 hour later (15). Con-
trol animals received an equivalent amount of nor-
mal rabbit IgG, in place of the anti-mBP180 IgG. The
animals were analyzed 12 hours after the IgG injec-
tions, as described above.
MC reconstitution. Kitw/Kitw-v mice were repaired of their
MC deficiency selectively and locally by the injection of
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growth factor–dependent bone marrow–derived cultured
MCs into the skin (24, 25). Briefly, femoral bone marrow
cells from congenic MC+/+ mice were maintained in vitro
for 4 weeks in RPMI 1640 complete medium (Life Tech-
nologies Inc., Grand Island, New York, USA) supple-
mented with 20% WEHI-3–conditioned medium until
MCs represented more than 95% of the total cells as deter-
mined by toluidine blue staining and flow cytometry
analysis using antibodies specific for MC cell-surface
markers FcεRI, c-Kit, and CD13 (25). Murine IgE and rat
anti-mouse IgE were purchased from Southern Biotech-
nology Associates (Birmingham, Alabama, USA). FITC-
labeled rat anti-mouse c-Kit and FITC-labeled rat anti-
mouse CD13 were obtained from BD PharMingen (San
Diego, California, USA). MCs (1 × 106 in 20 µl of medium)
were injected intradermally into the right ears of MC-defi-
cient mice. Media alone (20 µl) were injected intradermal-
ly into the left ears of the same mice as negative control.
This procedure selectively and locally reconstitute dermal
MC population without systemic effects (24). To confirm
MC reconstitution, skin sections from MC-injected sites
were stained by toluidin blue. Ten weeks after adoptive
transfer of MCs, both ears of the mice were injected intra-
dermally with pathogenic anti-BP180 IgG (2 mg/20
µl/site). Twenty-four hours later, ear skin biopsies were
obtained and analyzed by H&E, toluidine blue staining,
and MPO enzyme assay as described above.
Statistical analysis. The data are expressed as mean ±
SEM and were analyzed using the Student’s paired t
test. A P value less than 0.05 was considered significant.
Results
MC degranulation precedes neutrophilic infiltration and sub-
sequent dermal-epidermal separation. We first determined
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Figure 1
Time-course of MC degranulation in MC-sufficient mice injected
intradermally with pathogenic rabbit anti-murine BP180 IgG and
assessed 0–12 hours after injection. (a) Toluidine blue–stained sec-
tions showing progression of MC degranulation and separation of the
epidermis from the dermis. d, dermis; e, epidermis; v, vesicle; arrow,
site of antibody labeling. ×400. (b and c) Electron micrographs show
degranulation of MCs in dermis of mice injected with pathogenic IgG.
An MC in control animals (b) has a number of large cytoplasmic gran-
ules that appear in different density, whereas another MC from path-
ogenic IgG-injected animal (c) presents many empty vacuoles that
apparently resulted from degranulation. Numerous microvilli are
observed in the plasma membrane of degranulated MCs, indicating
the activated cell status. (d) The MCs in the dermis were counted and
classified as degranulated (>10% of the granules exhibiting fusion or
discharge) or normal (see Methods). MC degranulation reached the
peak level at 1–2 hours after pathogenic IgG injection. (e) Skin MPO
activity (mean ± SEM) data reveal the onset of PMN infiltration at 2
hours after IgG injection (n = 5 for each group shown).
Figure 2
Clinical and immunohistological analysis of neonatal MC-deficient
and -sufficient mice injected with pathogenic anti-mBP180 IgG. The
anti-mBP180 IgG (2.5 mg/g body weight) induced extensive blistering
disease in MC-sufficient (+/+) mice (a). The skin of these animals
showed linear deposition of rabbit IgG (b) and murine C3 (c) at the
BMZ, as determined by direct IF. Toluidine blue staining revealed epi-
dermal-dermal separation with MC degranulation (d). In contrast,
MC-deficient (MgfSl/MgfSl-d) mice injected intradermally with patho-
genic IgG showed no evidence of skin disease (e). Direct IF demon-
strated BMZ deposition of rabbit IgG (f) and murine C3 (g). Toluidine
blue staining showed no epidermal-dermal separation and absence of
MCs (h). d, dermis; e, epidermis; v, vesicle; black arrow in a and e, site
of clinical blister; white arrow, site of antibody labeling; black arrow in
d and h, site of BMZ. ×400. Inset in d is a lower-magnification micro-
graph showing the edge of a subepidermal vesicle. ×100.
whether and when MC infiltration and degranulation
occur in experimental BP and how these events are
related to PMN infiltration and subepidermal blister-
ing over the 12-hour period after intradermal injection
of pathogenic anti-mBP180 IgG. Five animals were
used at each time point. Deposition of rabbit IgG and
murine C3 at the cutaneous BMZ is
first observed 1–2 hours after IgG
injection (15). At 4 hours, an early
stage of dermal-epidermal separa-
tion was seen histologically (Figure
1a). By 8 hours, relatively broad
subepidermal blister vesicles could
be seen, and complete detachment
of the epidermis from the dermis
occurred at 12 hours. Electron
microscopy (Figure 1, b and c)
revealed that MCs in the dermis of
control mice (Figure 1b) had a large
amount of cytoplasmic granules
that present a variety of appear-
ances. Large vacuoles, which were
obviously resulted from degranula-
tion of MCs, were easily detected in
the dermis of the diseased mice 2
hours after IgG injection (Figure
1c). Although we saw no significant
changes in MC abundance at any
time points. MC degranulation was
dramatic (Figure 1d). MC degranu-
lation occurred within 1 hour after
intradermal injection of anti-
mBP180 IgG and reached a peak
1–2 hours before the first evidence of neutrophil
recruitment to the skin site. PMN infiltration was first
detected at 2–3 hours, then increased progressively over
the next 5 hours, reaching a peak at 8 hours (Figure 1e).
MC-deficient mice are resistant to experimental BP. To
determine whether MCs participate in experimental BP,
we injected wild-type and MC-deficient mice with path-
ogenic IgG. The MC+/+ mice (n = 8) showed MC degran-
ulation by toluidine blue staining and developed histo-
logical and clinical blisters 12 hours after IgG injection
(Figure 2, a and d). In contrast, MC-deficient MgfSl/
MgfSl-d mice (n = 8) injected with pathogenic IgG had no
clinical or histological signs of blister formation (Figure
2, e and h), despite the fact that these animals showed
as much deposition of IgG and C3 at the BMZ as did
the wild-type mice (Figure 2, b, c, f, and g). Histological
examination exhibited neither subepidermal blistering
nor MC presence in the skin (Figure 2h). Similar phe-
notype was found in MC-deficient Kitw/Kitw-v mice when
injected with pathogenic IgG (Table 1). Given that both
strains of MC-deficient mice caused by distinct mecha-
nisms are resistant to experimental BP, these results
strongly suggest that MCs play an essential role in BP.
Reconstitution of MCs in skin restores BP in MC-deficient
mice. To directly demonstrate a requirement of MCs in
subepidermal blistering in experimental BP, we injected
pathogenic IgG into Kitw/Kitw-v mice (n = 6) locally
repaired of their MC deficiency by adoptive transfer of
cultured MCs derived from congenic MC+/+ mouse bone
marrow cells. MCs, infiltrating neutrophils, and subepi-
dermal blistering were found in the MC-reconstituted
right ears but not in the MC-deficient left ears (Figure 3
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Figure 3
Effect of MC reconstitution on neutrophil infiltration and subse-
quent subepidermal blistering in pathogenic anti-BP180 IgG-inject-
ed MC-deficient mice. Neutrophil infiltration and blister formation
were determined in the left (MC-deficient) (middle bar) and right
(MC-reconstituted) (bottom bar) ears of Kitw/Kitw-v mice that under-
went local reconstitution of the right ear with 1 × 106 bone marrow-
derived MC+/+ MCs10 weeks before pathogenic IgG injection (2
mg/ear). MC+/+ littermates (top bar) were also injected with the same
dose of IgG in the ear as positive control (see Methods for details).
Significantly elevated levels of MPO activity (mean ± SEM) were seen
in the right ear compared with the left ear of Kitw/Kitw-v mice. Like
MC+/+ mice, the right but not the left ear skin sections exhibited der-
mal-epidermal separation as determined by H&E staining. MPO
activity at 0 hours was 0.07 ± 0.01 for MC-deficient and 0.09 ± 0.02
(OD460nm/mg protein) for MC+/+ mice. (n = 6 for each group.) 
*P < 0.01, top vs. middle bar.
Table 1
The role of MCs in BP blister formation
Host miceA IgG injected Treatment Number of mice Disease activityB
Control IgG – 5 –
+/+ Pathogenic IgG – 12 3+
Pathogenic IgG Cromolyn 5 –
– 8 –
MgfSl/MgfSl-d Pathogenic IgG 5 × 105 PMNs 5 3+
hIL-8 5 3+
– 5 –
Kitw/Kitw-v Pathogenic IgG 5 × 105 PMNs 5 3+
hIL-8 5 3+
hIL-8 + cromolyn 5 3+
Kitw/Kitw-v Pathogenic IgG Medium (left ears) 6 –
1 × 106 MCs (right ears) 6 +
ANeonatal MC-deficient (MgfSl/MgfSl-d and Kitw/Kitw-v) and MC-sufficient control (MC+/+) mice were inject-
ed intradermally with either control IgG (R50) or pathogenic anti-mBP180 antibody (R621) (2.5 mg
per gram of body weight). The MC degranulation inhibitor cromolyn sodium (10 µg/g body weight) or
hIL-8 (50 ng/g body weight) was given intradermally. Purified mouse PMNs (5 × 105 cells/50 µl) from
MgfSl/MgfSl-d or MC+/+ mice were given intradermally 2 hours after IgG injection. For MC reconstitution
experiments, 1 × 106 MCs from MC+/+ mice were injected into the right ears of Kitw/Kitw-v mice (6 weeks
old). A total of 20 µl of MC culture medium was injected into the left ears of the same mice as negative
control. Ten weeks later, the mice were challenged with pathogenic IgG (2 mg/site) and examined 24
hours after IgG injection. BDisease activity was scored as described in Methods.
and Table 1). The increase of neutrophils in the MC-
reconstituted site was significantly higher than in the
MC-deficient site (P < 0.01). These results clearly show
that neutrophil infiltration and subsequent blister for-
mation triggered by anti-BP180 IgG are indeed MC
dependent. The MC reconstitution data also rule out
the possibility that resistance of MC-deficient mice to
experimental BP is due to other unidentified defects
resulting from the c-Kit mutations in Kitw/Kitw-v mice,
besides the MC deficiency of these animals.
Pathogenic anti-mBP180 IgG induces subepidermal blistering
in MC-deficient mice reconstituted with PMNs from MC-defi-
cient mice or by intradermal injection of the neutrophil chemoat-
tractant IL-8. If the major function of MCs in experimen-
tal BP is to recruit PMNs from circulation to the
IgG-injection site, then artificially recruiting them to the
dermis of the MC-deficient mice should circumvent the
requirement for MCs for disease phenotype. This is
exactly what we observed when we injected MC-deficient
mice with pathogenic IgG and reconstituted them with
mouse PMNs. The MC-deficient mice reconstituted with
5 × 105 PMNs from wild-type mice (n = 5) developed
subepidermal blisters 12 hours after IgG injection (Fig-
ure 4). The MC-deficient mice reconstituted with 5 × 105
PMNs from MC-deficient mice (n = 5) also became sus-
ceptible to pathogenic anti-mBP180 IgG, with a similar
disease score indicating that PMNs are normal in MC
deficiency (Table 1). In addition, MC-deficient mice 
(n = 5) given an intradermal injection of IL-8 before, or
coincident with, the treatment with anti-mBP180 IgG,
developed extensive blisters 12 hours later (Figure 5 and
Table 1). The skin of these mice showed typical subepi-
dermal separation and morphological and biochemical
evidence of neutrophilic infiltration of the dermis (Fig-
ure 5). The mean MPO activity level in skin extracts of
MC-deficient mice coinjected with anti-mBP180 IgG
and IL-8 was 1.14 ± 0.18 OD460nm/mg protein (Figure 5),
compared with 0.29 ± 0.02 (P < 0.01) for skin from the
mice injected only with anti-mBP180 IgG. Taken togeth-
er, these results clearly demonstrate that MCs mainly
participate in PMN recruitment in experimental BP.
An inhibitor of MC degranulation blocks neutrophil recruit-
ment and subsequent blistering. Extensive MC degranula-
tion takes place in the dermis of mice injected with
pathogenic IgG. But is it required? Neonatal wild-type
mice, which were pretreated with vehicle, followed by
pathogenic anti-mBP180 IgG (n = 5) 90 minutes later,
developed intense blisters by 12 hours (Table 1). In con-
trast, mice treated with the MC degranulation inhibitor
cromolyn sodium, followed by pathogenic IgG (n = 5)
did not develop skin lesions (Table 1). The skin of the
cromolyn sodium–treated animals showed no evidence
of subepidermal vesiculation and minimal MC degran-
ulation, despite the presence of high levels of circulat-
ing rabbit anti-BP180 antibodies, in situ deposition of
rabbit IgG and murine C3 at the BMZ (data not shown).
The cromolyn sodium–treated mice had significantly
reduced PMN infiltration, compared with control mice.
The relative mean MPO levels for mice treated with cro-
molyn sodium at 2, 4, and 12 hours were 0.23 ± 0.02,
0.26 ± 0.03, and 0.43 ± 0.05 OD460nm/mg protein, respec-
tively, whereas the MPO levels for the control groups
were 0.20 ± 0.03 (P > 0.05), 0.41 ± 0.05 (P < 0.05), and 1.13
± 0.17 OD460nm/mg protein (P < 0.01), respectively. This
is very similar to the phenotype seen in MC-deficient
mice. We also ruled out the possibility that cromolyn
may directly interfere with development of BP rather
than blocking MC degranulation by pretreatment of
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Figure 4
Experimental BP in MC-deficient mice reconstituted with normal
PMNs. Pathogenic rabbit anti-mBP180 IgG (intradermal injection,
2.5 mg/g body weight) induced skin blisters in MC-sufficient (+/+)
mice (a) and toluidine blue staining showed the presence of MCs (b).
Anti-mBP180 IgG failed to trigger the skin lesions in MC-deficient
MgfSl/MgfSl-d mice (c), but R621 IgG triggered the skin disease in
MgfSl/MgfSl-d mice reconstituted with PMNs from MC+/+ mice (e) or
MC-deficient mice (data not shown). Toluidine blue staining con-
firmed the MC deficiency in these animals (d and f).
Figure 5
In vivo reconstitution of PMNs at the tissue site by intradermal injec-
tion of IL-8 restores the pathogenic effect of anti-BP180 IgG in neona-
tal MC-deficient mice. MC-sufficient (+/+) (bar 1) or MC-deficient
MgfSl/MgfSl-d mice (bars 2–6) were injected intradermally with either
pathogenic anti-mBP 180 IgG alone (bars 1 and 4), control rabbit IgG
alone (bar 2), hIL-8 alone (bar 3), or IgG plus hIL-8 (bars 5 and 6).
MC-deficient mice coinjected with IL-8 and anti-mBP 180 IgG (bar 5),
but not the control rabbit IgG (bar 6), developed subepidermal blis-
ters. The IgG dose was 2.5 mg/g body weight. Doses for IL-8 was 50
ng/mouse. Tissue MPO activity (mean ± SEM) in skin at the injection
site was determined 12 hours after IgG administration. Each group of
mice (n = 5) without injection yielded an average of MPO activity of
0.08 ± 0.02 OD460nm/mg protein. *P < 0.01, Student’s t -test for
paired samples (bar 4 versus bar 5). See Methods for details.
MC-deficient mice with cromolyn followed by injection
of pathogenic IgG plus IL-8. There was no difference in
PMN influx and disease scores between MC-deficient
mice coinjected with pathogenic IgG and IL-8 with or
without cromolyn pretreatment (Table 1). Because ini-
tial PMN recruitment is impaired in both MC-deficient
mice and in MC-sufficient mice treated with cromolyn
sodium, MCs appear to play a key role in early steps of
recruiting PMNs as a consequence of degranulation.
Complement is required for MC degranulation and PMN
recruitment. The requirement for neutrophil recruit-
ment requires MCs. Complement is required for blister
formation. Complement fragments can both induce
PMN chemotaxis and MC degranulation (26). Because
complement was still present at the BMZ in MC-defi-
cient mice, we next determined whether complement
activation was a key element for MC degranulation or
PMN recruitment. As a genetic test of whether MC-
mediated PMN infiltration depends on complement
activation, C5+ and C5– mice were injected intrader-
mally with pathogenic IgG. C5+ but not C5– mice devel-
oped subepidermal blisters with a neutrophil infiltrate
12 hours after IgG injection, as shown previously (14).
Toluidine blue staining revealed extensive MC degran-
ulation in the dermis at 2 hours (Figure 6a) and 12
hours (Figure 6b). At 2 hours, 68% of MC were degran-
ulated and 17% at 12 hours, in C5+ mice. In contrast,
C5– mice exhibited a minimal level of MC degranula-
tion in the dermis at 2 hours and 12 hours (Figure 6, c
and d). C5+ mice injected with F(ab′)2 fragments of the
pathogenic IgG also lacked MC degranulation in the
dermis (data not shown). We previously found that C5-
sufficient mice injected with pathogenic IgG F(ab′)2
fragments, which do not fix complement, have F(ab′)2,
but no C3 deposited at the BMZ and have only back-
ground levels of neutrophil infiltration and no signs of
skin lesions (14). Thus, MC degranulation triggered by
anti-BP 180 IgG depends on complement activation.
We next asked whether PMN infiltration occurred
when complement was activated in the absence of MC.
Intradermal PMN infiltration, quantified by MPO
assay, was significantly lower in MC-deficient mice
compared with wild-type controls both at 4 hours and
12 hours after IgG injection (Figure 7). Taken togeth-
er, these results demonstrate a requirement of MCs for
subepidermal blistering in experimental BP and sug-
gest that the role of complement activation may be to
activate MC degranulation.
Discussion
The aim of the present study was to assess the role of
MCs in the pathogenesis of subepidermal blister forma-
tion in a mouse model of BP. The presence and degran-
ulation of MCs at the BP lesional sites were first report-
ed by Wintroub et al. in 1978 (7) and subsequently
confirmed by other investigators (9, 27, 28). However,
until our study, the functional significance of MCs in BP
remained obscure. In this report, we find that the major
role for MCs is as mediators in PMN recruitment and,
thus, in subepidermal blister formation triggered by
anti-mBP180 IgG. Pathogenic IgG failed to induce dis-
ease phenotype in MC-deficient mice. Not only did MC
degranulate extensively in experimental BP (81% at the
peak), but this degranulation was necessary for blister-
ing. We have previously demonstrated that subepider-
mal blistering depends on complement activation (14)
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Figure 6
MC degranulation depends on complement activation. Neonatal C5-
sufficient (a and b) and C5-deficient mice (c and d) were injected
intradermally with pathogenic IgG R621 (2.5 mg/g body weight).
C5+ (b) but not C5– mice (d) developed subepidermal blisters 12
hours after IgG injection. Toluidine blue staining analysis showed MC
degranulation in the skin of C5+ mice at 2 hours (a) and 12 hours
(b), whereas minimal levels of MC degranulation were seen in the
dermis of C5– mice (b and d). d, dermis; e, epidermis; v, vesicle;
arrow, site of basal keratinocyte. Original magnification ×400 (a and
b), ×200 (c and d).
Figure 7
MPO activity of skin extracts from mice injected intradermally with
pathogenic rabbit anti-mBP180 IgG. Neonatal MC-deficient
MgfSl/MgfSl-d (bars 1 and 2), Kitw/Kitw-v (bars 3 and 4), and congenic
normal (+/+) mice (bars 5 and 6) received 2.5 mg/g body weight
pathogenic anti-mBP180 IgG. Tissue MPO activities (mean ± SEM)
in the injection sites were determined 4 hours (bars 1, 3, and 5) and
12 hours (bars 2, 4, and 6) after the IgG injection (n = 5 for each
group). *P < 0.01; **P < 0.005. Student’s t test for paired samples
(bar 2 or 4 versus bar 6). The MPO values shown were corrected for
control IgG controls. Each group of mice injected with control IgG
yielded an average MPO activity of ∼0.13 OD460nm/mg protein.
and neutrophil infiltration into the dermis (15). We now
found that complement activating is required for MC
degranulation. Injection of cromolyn sodium, which
inhibits MC degranulation, prevented PMN recruitment
and, subsequently, subepidermal blistering.
In these studies, we used two different strains of MC-
deficient mice caused by distinct mechanisms:
MgfSl/MgfSl-d mice have mutations in the c-Kit ligand MC
growth factor (stem cell factor) and Kitw/Kitw-v mice have
mutations in c-Kit. Owing to the nature of the muta-
tions, transplantation of congenic MC+/+ MCs repairs the
MC deficiency of Kitw/Kitw-v, but not MgfSl/MgfSl-d mice
(16, 29). We found that both strains were resistant to the
pathogenic activity of anti-BP180 IgG, independently
implicating a critical role in subepidermal blistering. To
demonstrate directly that MCs are absolutely required
for the disease, we showed that MC-deficient Kitw/Kitw-v
mice, which had been locally and selectively reconstitut-
ed with MCs from the congenic MC+/+ mice, like their
normal control MC+/+ littermates, developed BP when
injected with pathogenic antibodies.
MC degranulation precedes PMN infiltration and sub-
sequent DEJ separation. Our results show a significant
reduction in PMN infiltration both in the early and late
stages of the disease process in MC-deficient mice.
Blocking MC degranulation significantly reduced PMN
recruitment into the skin and completely abolished
experimental BP. Furthermore, when a potent PMN
chemoattractant, such as IL-8, was coadministered with
the anti-mBP180 antibodies, the MC-deficient mice
showed both clinical and histological evidence of neu-
trophilic infiltration of the dermis and subepidermal
blistering. Taken together, these findings provide the
first in vivo evidence that subepidermal blistering
induced by pathogenic anti-mBP180 antibodies depends
on MCs, which, by degranulation step, play an essential
role in recruiting neutrophils to the target tissue.
C3a and C5a have been widely used to stimulate acti-
vation and chemotaxis of PMNs (26). However, C5a also
can induce MC degranulation (26). In human BP stud-
ies, complement components are fixed on the DEJ and
are present in the blister fluid (1). Indeed, mice that are
genetically deficient in C5 are resistant to experimental
BP and show a significant reduction in PMN infiltra-
tion into the dermis relative to C5-sufficient controls
(14). In the present study, we found that C5 deficiency
completely abolished MC degranulation. These data
suggest that a key function of complement system is
MC activation triggered by pathogenic anti-BP 180 IgG.
However, C5a also can induce PMN chemotaxis (26).
From our data showing anti-mBP180 IgG-injected MC-
deficient mice had 31% of MPO activity, and MC-suffi-
cient mice treated with cromolyn sodium had 38% of
MPO activity of diseased mice, we can conclude that
MC degradation–dependent mechanism accounts for
approximately two thirds of the PMN infiltration into
the skin. Thus anti-mBP180 IgG triggers PMN infiltra-
tion by both an MC-dependent and an MC-independ-
ent pathway. But how do MCs regulate PMN infiltra-
tion? MCs can produce a variety of mediators such as
leukotrienes, platelet-activating factor, and cytokines
that contribute directly or indirectly to PMN recruit-
ment (30, 31). In fact, high levels of histamine,
leukotriene B4, IL-1, -2, -5, and -6, and TNF-α are pres-
ent in BP blister fluids (11, 32–37). The MC-independ-
ent pathway probably involves direct activation of
PMNs by the complement fragments activated by inter-
action between anti-mBP180 and its target antigen.
Support for our conclusion that the major role of MCs
in experimental BP is as mediators of PMN infiltration
comes from our findings that artificially recruiting
PMNs to the dermis of MC-deficient mice circumvents
the requirement for MCs for disease phenotype. These
data are consistent with our previous observations that
subepidermal blistering depends on PMNs, which are
recruited into the skin site and, upon activation, release
neutrophil elastase (38) and gelatinase B to damage DEJ
(23). However, it is also possible that MCs contribute to
other aspects of the pathogenic process. MCs could con-
tribute to tissue damage directly by cleaving structural
proteins in the DEJ or indirectly by activating gelatinase
B in experimental BP. MCs contain numerous prote-
olytic enzymes (30). Activation and degranulation of
MCs are associated with matrix degradation (39). The
MC-specific serine protease MCP-4 (chymase) can acti-
vate gelatinase B, a protease required for BP (40).
It is known that our present studies, however, have not
yet uncovered the mechanisms by which anti-BP180
IgG- and C′-dependent MC degranulation is linked to
the neutrophils infiltration in experimental BP.
In summary, our present study provides direct evi-
dence that subepidermal blistering triggered by anti-
mBP180 antibodies is MC dependent. MCs participate
in acute and chronic inflammatory responses (28,
41–44). Our current data extend their function to an
autoimmune blistering disease, BP. MC products, such
as TNF-α and MC tryptase, have been linked directly to
neutrophils influx (45–47). Further investigations will
be necessary to identify the MC-released molecule(s),
which play a direct role in recruiting neutrophils down-
stream of anti-BP180 IgG- and complement-dependent
MC degranulation, so we can better understand the
immunopathogenesis of these complex reactions in
experimental BP. Inhibition of MC degranulation could
be a new therapeutic strategy for BP. These findings may
have significant implications for other autoimmune
subepidermal blistering disorders in which an anti-
BP180 immune response and MCs have been implicat-
ed, such as cicatricial pemphigoid, linear IgA bullous
dermatosis, lichen planus pemphigoid, epidermolysis
bullosa acquisita, and lupus skin conditions (48–53).
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